<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncologist</journal-id><journal-id journal-id-type="iso-abbrev">Oncologist</journal-id><journal-id journal-id-type="hwp">theoncologist</journal-id><journal-id journal-id-type="pmc">oncologist</journal-id><journal-id journal-id-type="publisher-id">The Oncologist</journal-id><journal-title-group><journal-title>The Oncologist</journal-title></journal-title-group><issn pub-type="ppub">1083-7159</issn><issn pub-type="epub">1549-490X</issn><publisher><publisher-name>AlphaMed Press</publisher-name><publisher-loc>Durham, NC, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27694157</article-id><article-id pub-id-type="pmc">5061534</article-id><article-id pub-id-type="publisher-id">T16220CTR</article-id><article-id pub-id-type="doi">10.1634/theoncologist.2016-0220</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>4</subject><subject>31</subject><subject>14</subject><subject>4</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical Trial Results</subject></subj-group></article-categories><title-group><article-title>A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer</article-title><alt-title alt-title-type="short">Linsitinib Versus Topotecan in SCLC Patients</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Chiappori</surname><given-names>Alberto A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Otterson</surname><given-names>Gregory A.</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dowlati</surname><given-names>Afshin</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Traynor</surname><given-names>Anne M.</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Horn</surname><given-names>Leora</given-names></name><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Owonikoko</surname><given-names>Taofeek K.</given-names></name><xref ref-type="aff" rid="aff6"><sup>f</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ross</surname><given-names>Helen J.</given-names></name><xref ref-type="aff" rid="aff7"><sup>g</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hann</surname><given-names>Christine L.</given-names></name><xref ref-type="aff" rid="aff8"><sup>h</sup></xref></contrib><contrib contrib-type="author"><name><surname>Abu Hejleh</surname><given-names>Taher</given-names></name><xref ref-type="aff" rid="aff9"><sup>i</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nieva</surname><given-names>Jorge</given-names></name><xref ref-type="aff" rid="aff10"><sup>j</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Xiuhua</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Schell</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sullivan</surname><given-names>Daniel M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><aff id="aff1"><sup>a</sup>H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA</aff><aff id="aff2"><sup>b</sup>Ohio State University, Columbus, Ohio, USA</aff><aff id="aff3"><sup>c</sup>University Hospitals Case Medical Center, Cleveland, Ohio, USA</aff><aff id="aff4"><sup>d</sup>University of Wisconsin, Madison, Wisconsin, USA</aff><aff id="aff5"><sup>e</sup>Vanderbilt University, Nashville, Tennessee, USA</aff><aff id="aff6"><sup>f</sup>Winship Cancer Institute of Emory University, Atlanta, Georgia, USA</aff><aff id="aff7"><sup>g</sup>Mayo Clinic, Scottsdale, Arizona, USA</aff><aff id="aff8"><sup>h</sup>Johns Hopkins University, Baltimore, Maryland, USA</aff><aff id="aff9"><sup>i</sup>University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA</aff><aff id="aff10"><sup>j</sup>University of Southern California, Los Angeles, California, USA</aff></contrib-group><author-notes><corresp id="cor1">Correspondence: Alberto A. Chiappori, M.D., H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida 33612, USA. Telephone: <phone>813-745-3050</phone>; E-Mail: <email>alberto.chiappori@moffitt.org</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>30</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>30</day><month>9</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>21</volume><issue>10</issue><fpage>1163</fpage><lpage>1164e</lpage><history><date date-type="received"><day>12</day><month>5</month><year>2016</year></date><date date-type="accepted"><day>22</day><month>6</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9;AlphaMed Press; the data published online to support this summary is the property of the authors.</copyright-statement><copyright-year>2016</copyright-year></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="theoncologist_16220CTR.pdf"/><abstract><sec><title>Lessons Learned</title><p><list list-type="bullet"><list-item><p>Targeted therapy options for SCLC patients are limited; no agent, thus far, has resulted in a strategy promising enough to progress to phase III trials.</p></list-item><list-item><p>Linsitinib, a potent insulin growth factor-1-receptor tyrosine kinase inhibitor, may be one agent with activity against SCLC.</p></list-item><list-item><p>Despite lack of a reliable predictive biomarker in this disease, which may have partly contributed to the negative outcome reported here, linsitinib, although safe, showed no clinical activity in unselected, relapsed SCLC patients.</p></list-item></list></p></sec><sec><title>Background.</title><p>Treatment of relapsed small-cell lung cancer (SCLC) remains suboptimal. Insulin growth factor-1 receptor (IGF-1R) signaling plays a role in growth, survival, and chemoresistance in SCLC. Linsitinib is a potent IGF-1R tyrosine kinase inhibitor that potentially may be active against SCLC.</p></sec><sec><title>Methods.</title><p>In this phase II study, 8 eligible patients were randomly assigned in a 1:2 ratio to topotecan (1.5 mg/m<sup>2</sup> intravenously or 2.3 mg/m<sup>2</sup> orally, daily for 5 days for 4 cycles) or linsitinib (150 mg orally twice daily until progression). The primary endpoint was progression-free survival. Patients with relapsed SCLC, platinum sensitive or resistant, performance status (PS) 0&#x02013;2, and adequate hematologic, renal, and hepatic function were enrolled. Patients with diabetes, cirrhosis, and those taking insulinotropic agents were excluded. Crossover to linsitinib was allowed at progression.</p></sec><sec><title>Results.</title><p>Fifteen patients received topotecan (8 resistant, 3 with PS 2) and 29 received linsitinib (16 resistant, 5 with PS 2). Two partial responses were observed with topotecan. Only 4 of 15 patients with topotecan and 1 of 29 with linsitinib achieved stable disease. Median progression-free survival was 3.0 (95% confidence interval [CI], 1.5&#x02013;3.6) and 1.2 (95% CI, 1.1&#x02013;1.4) months for topotecan and linsitinib, respectively (<italic>p</italic> = .0001). Median survival was 5.3 (95% CI, 2.2&#x02013;7.6) and 3.4 (95% CI, 1.8&#x02013;5.6) months for topotecan and linsitinib, respectively (<italic>p</italic> = .71). Grade 3/4 adverse events (&#x0003e;5% incidence) included anemia, thrombocytopenia, neutropenia/leukopenia, diarrhea, fatigue, dehydration, and hypokalemia for topotecan; and thrombocytopenia, fatigue, and alanine aminotransferase/aspartate aminotransferase elevations for linsitinib.</p></sec><sec><title>Conclusion.</title><p>Linsitinib was safe but showed no clinical activity in unselected, relapsed SCLC patients.</p></sec></abstract><trans-abstract xml:lang="zh"><p>&#x04f5c;&#x08005;&#x0603b;&#x07ed3;</p><p>&#x07ecf;&#x09a8c;</p><p>&#x02022; &#x05c0f;&#x07ec6;&#x080de;&#x080ba;&#x0764c;(SCLC)&#x060a3;&#x08005;&#x09776;&#x05411;&#x06cbb;&#x07597;&#x07684;&#x09009;&#x062e9;&#x0975e;&#x05e38;&#x06709;&#x09650;, &#x08fc4;&#x04eca;&#x05c1a;&#x065e0;&#x04e00;&#x079cd;&#x05236;&#x05242;&#x088ab;&#x0770b;&#x0597d;&#x06709;&#x05145;&#x08db3;&#x07684;&#x06f5c;&#x0529b;&#x08fdb;&#x05165;III&#x0671f;&#x04e34;&#x05e8a;&#x08bd5;&#x09a8c;&#x03002;</p><p>&#x02022; Linsitinib&#x0662f;&#x05f3a;&#x06548;&#x07684;&#x080f0;&#x05c9b;&#x07d20;&#x0751f;&#x0957f;&#x056e0;&#x05b50;1&#x053d7;&#x04f53;&#x0916a;&#x06c28;&#x09178;&#x06fc0;&#x09176;&#x06291;&#x05236;&#x05242;, &#x053ef;&#x080fd;&#x05bf9;SCLC&#x05177;&#x06709;&#x06cbb;&#x07597;&#x06d3b;&#x06027;&#x03002;</p><p>&#x02022; &#x0672c;&#x06587;&#x07684;&#x09634;&#x06027;&#x07ed3;&#x0679c;&#x05728;&#x04e00;&#x05b9a;&#x07a0b;&#x05ea6;&#x04e0a;&#x053ef;&#x080fd;&#x0662f;&#x07531;SCLC&#x07f3a;&#x04e4f;&#x053ef;&#x09760;&#x07684;&#x09884;&#x06d4b;&#x06027;&#x0751f;&#x07269;&#x06807;&#x08bb0;&#x07269;&#x06240;&#x081f4;,&#x05c3d;&#x07ba1;linsitinib&#x05728;&#x0672a;&#x07ecf;&#x09009;&#x062e9;&#x07684;&#x0590d;&#x053d1;&#x06027;SCLC&#x060a3;&#x08005;&#x04e2d;&#x0662f;&#x05b89;&#x05168;&#x07684;, &#x04f46;&#x05e76;&#x0672a;&#x0663e;&#x0793a;&#x051fa;&#x04e34;&#x05e8a;&#x06d3b;&#x06027;&#x03002;</p><p>&#x06458;&#x08981;</p><p><bold><italic>&#x080cc;&#x0666f;.</italic></bold> &#x0590d;&#x053d1;&#x06027;&#x05c0f;&#x07ec6;&#x080de;&#x080ba;&#x0764c;(SCLC)&#x07684;&#x06cbb;&#x07597;&#x04ecd;&#x07136;&#x04e0d;&#x05c3d;&#x04eba;&#x0610f;&#x03002;&#x080f0;&#x05c9b;&#x07d20;&#x0751f;&#x0957f;&#x056e0;&#x05b50;1&#x053d7;&#x04f53;(IGF-1R)&#x04fe1;&#x053f7;&#x0901a;&#x08def;&#x05728;SCLC&#x07684;&#x0751f;&#x0957f;&#x03001;&#x05b58;&#x06d3b;&#x053ca;&#x05316;&#x07597;&#x08010;&#x0836f;&#x04e2d;&#x053d1;&#x06325;&#x04f5c;&#x07528;&#x03002;Linsitinib&#x0662f;&#x05f3a;&#x06548;&#x07684;IGF-1R&#x0916a;&#x06c28;&#x09178;&#x06fc0;&#x09176;&#x06291;&#x05236;&#x05242;, &#x053ef;&#x080fd;&#x05bf9;SCLC&#x05177;&#x06709;&#x06cbb;&#x07597;&#x06d3b;&#x06027;&#x03002;</p><p><bold><italic>&#x065b9;&#x06cd5;.</italic></bold> &#x0672c;&#x09879;II&#x0671f;&#x07814;&#x07a76;&#x04e2d;, 8&#x04f8b;&#x07b26;&#x05408;&#x05165;&#x09009;&#x06761;&#x04ef6;&#x07684;&#x060a3;&#x08005;&#x06309;1:2&#x06bd4;&#x04f8b;&#x0968f;&#x0673a;&#x063a5;&#x053d7;&#x062d3;&#x06251;&#x066ff;&#x05eb7;(1.5 mg/m<sup>2</sup>&#x09759;&#x08109;&#x06ce8;&#x05c04;&#x06216;2.3 mg/m<sup>2</sup>&#x053e3;&#x0670d;, &#x06bcf;&#x065e5;1&#x06b21;&#x000d7;5&#x05929;, &#x05171;4&#x05468;&#x0671f;)&#x06216;linsitinib(150 mg&#x053e3;&#x0670d;, &#x06bcf;&#x065e5;2&#x06b21;&#x076f4;&#x081f3;&#x053d1;&#x0751f;&#x075be;&#x075c5;&#x08fdb;&#x05c55;)&#x06cbb;&#x07597;&#x03002;&#x04e3b;&#x08981;&#x07ec8;&#x070b9;&#x04e3a;&#x065e0;&#x08fdb;&#x05c55;&#x0751f;&#x05b58;(PFS)&#x03002;&#x07814;&#x07a76;&#x05165;&#x09009;&#x04e86;&#x094c2;&#x07c7b;&#x06cbb;&#x07597;&#x0654f;&#x0611f;&#x06216;&#x062b5;&#x06297;&#x03001;&#x04f53;&#x080fd;&#x072b6;&#x06001;(PS)&#x08bc4;&#x05206;0&#x0223c;2&#x05206;&#x03001;&#x05177;&#x06709;&#x08db3;&#x0591f;&#x09aa8;&#x09ad3;&#x0548c;&#x0809d;&#x080be;&#x0529f;&#x080fd;&#x07684;&#x0590d;&#x053d1;&#x06027;SCLC&#x060a3;&#x08005;&#x03002;&#x07814;&#x07a76;&#x06392;&#x09664;&#x04e86;&#x05408;&#x05e76;&#x07cd6;&#x05c3f;&#x075c5;&#x03001;&#x0809d;&#x0786c;&#x05316;, &#x04ee5;&#x053ca;&#x0670d;&#x07528;&#x080f0;&#x05c9b;&#x07d20;&#x04fc3;&#x06ccc;&#x05242;&#x07684;&#x060a3;&#x08005;&#x03002;&#x062d3;&#x06251;&#x066ff;&#x05eb7;&#x07ec4;&#x060a3;&#x08005;&#x05728;&#x053d1;&#x0751f;&#x075be;&#x075c5;&#x08fdb;&#x05c55;&#x0540e;, &#x05141;&#x08bb8;&#x04ea4;&#x053c9;&#x081f3;linsitinib&#x07ec4;&#x03002;</p><p><bold><italic>&#x07ed3;&#x0679c;.</italic></bold> 15&#x04f8b;&#x060a3;&#x08005;&#x063a5;&#x053d7;&#x062d3;&#x06251;&#x066ff;&#x05eb7;&#x06cbb;&#x07597;(8&#x04f8b;&#x08010;&#x0836f;, 3&#x04f8b;PS&#x04e3a;2&#x05206;), 29&#x04f8b;&#x060a3;&#x08005;&#x063a5;&#x053d7;linsitinib&#x06cbb;&#x07597;(16&#x04f8b;&#x08010;&#x0836f;, 5&#x04f8b;PS&#x04e3a;2&#x05206;)&#x03002;&#x062d3;&#x06251;&#x066ff;&#x05eb7;&#x07ec4;&#x06709;2&#x04f8b;&#x060a3;&#x08005;&#x08fbe;&#x05230;&#x090e8;&#x05206;&#x07f13;&#x089e3;&#x03002;&#x04ec5;&#x06709;&#x062d3;&#x06251;&#x066ff;&#x05eb7;&#x07ec4;4/15&#x04f8b;&#x060a3;&#x08005;&#x03001;linsitinib&#x07ec4;1/29&#x04f8b;&#x060a3;&#x08005;&#x08fbe;&#x05230;&#x075be;&#x075c5;&#x07a33;&#x05b9a;&#x03002;&#x04e2d;&#x04f4d;PFS&#x05206;&#x0522b;&#x04e3a;&#x062d3;&#x06251;&#x066ff;&#x05eb7;&#x07ec4;3.0&#x04e2a;&#x06708;[95%&#x07f6e;&#x04fe1;&#x0533a;&#x095f4;(CI): 1.5&#x0223c;3.6], linsitinib&#x07ec4;1.2&#x04e2a;&#x06708;(95% CI:1.1&#x0223c;1.4, <italic>P</italic>=0.000 1)&#x03002;&#x062d3;&#x06251;&#x066ff;&#x05eb7;&#x07ec4;&#x0548c;linsitinib&#x07ec4;&#x04e2d;&#x04f4d;&#x0603b;&#x0751f;&#x05b58;&#x05206;&#x0522b;&#x04e3a;5.3&#x04e2a;&#x06708;(95% CI:2.2&#x0223c;7.6)&#x0548c;3.4&#x04e2a;&#x06708;(95% CI:1.8&#x0223c;5.6, <italic>P</italic>=0.71)&#x03002;3/4&#x07ea7;&#x04e0d;&#x0826f;&#x04e8b;&#x04ef6;(&#x053d1;&#x0751f;&#x07387;&#x0003e;5%)&#x04e8e;&#x062d3;&#x06251;&#x066ff;&#x05eb7;&#x07ec4;&#x04e3a;&#x08d2b;&#x08840;&#x03001;&#x08840;&#x05c0f;&#x0677f;&#x051cf;&#x05c11;&#x03001;&#x04e2d;&#x06027;&#x07c92;&#x07ec6;&#x080de;&#x051cf;&#x05c11;/&#x0767d;&#x07ec6;&#x080de;&#x051cf;&#x05c11;&#x03001;&#x08179;&#x06cfb;&#x03001;&#x075b2;&#x04e4f;&#x03001;&#x08131;&#x06c34;&#x04ee5;&#x053ca;&#x04f4e;&#x094be;&#x08840;&#x075c7;, &#x04e8e;linsitinib&#x07ec4;&#x04e3a;&#x08840;&#x05c0f;&#x0677f;&#x051cf;&#x05c11;&#x03001;&#x075b2;&#x04e4f;&#x03001;&#x04e19;&#x06c28;&#x09178;&#x06c28;&#x057fa;&#x08f6c;&#x079fb;&#x09176;/&#x05929;&#x051ac;&#x06c28;&#x09178;&#x06c28;&#x057fa;&#x08f6c;&#x079fb;&#x09176;&#x06c34;&#x05e73;&#x05347;&#x09ad8;&#x03002;</p><p><bold><italic>&#x07ed3;&#x08bba;.</italic></bold> Linsitinib&#x07528;&#x04e8e;&#x06cbb;&#x07597;&#x0672a;&#x07ecf;&#x09009;&#x062e9;&#x07684;&#x0590d;&#x053d1;&#x06027;SCLC&#x060a3;&#x08005;&#x0662f;&#x05b89;&#x05168;&#x07684;, &#x04f46;&#x0672a;&#x0663e;&#x0793a;&#x051fa;&#x04e34;&#x05e8a;&#x06d3b;&#x06027;&#x03002;<bold><italic>The Oncologist</italic></bold> 2016;21:1163&#x02013;1164e</p></trans-abstract><counts><page-count count="6"/></counts></article-meta></front><body><sec sec-type="discussion" id="s2"><title>Discussion</title><p>Improved understanding of the molecular mechanisms and signaling pathways involved in tumor development and progression, leading to identification of potential targets (receptors and/or ligands) for anticancer therapy and development of pharmacological agents able to interfere with these targetable pathways, has resulted in therapeutic benefit in non-small cell lung cancer (NSCLC). However, SCLC has proven less amenable to a targeted approach. Few studies have attempted targeted therapy in this disease, and none has produced a strategy promising enough to progress to phase III trials [<xref rid="B1" ref-type="bibr">1</xref>].</p><p>The progress achieved in NSCLC is clearly related to the presence of powerful, predictive biomarkers (e.g., EGFR, ALK) and to access to tissue where these biomarkers are identified. The former (predictive biomarkers) and the latter (tissue obtained from biopsies) are routinely not available in SCLC.</p><p>Recently, ERK phosphorylation (pERK) has been proposed as a marker of resistance to insulin growth factor-1 receptor (IGF-1R) inhibition in SCLC [<xref rid="B2" ref-type="bibr">2</xref>]; additionally, circulating tumor cells (CTCs) have been described as a prognostic marker [<xref rid="B3" ref-type="bibr">3</xref>] and used as a source of tumor material in patients with SCLC. Furthermore, [<sup>18</sup>F]fluorodeoxyglucose-positron emission tomography [<sup>18</sup>FDG-PET] has been reported to predict response to linsitinib in mouse models of preclinical lung cancer [<xref rid="B4" ref-type="bibr">4</xref>], with &#x0201c;metabolic burden&#x0201d; similarly measured by <sup>18</sup>FDG-PET scan also described as a prognostic factor in patients with SCLC [<xref rid="B5" ref-type="bibr">5</xref>]. Therefore, a reasonable personalized trial would be one in which patients with relapsed SCLC, selected by pERK expression in CTCs, are treated with linsitinib and followed with PET scans as surrogates of response and/or clinical benefit.</p><p>Unfortunately, failure of benefit with agents targeting IGF-1R, including linsitinib, has not been limited to relapsed SCLC. Indeed, the addition of monoclonal antibodies against IGF-1R, like cixutumumab (IMCA12); to platinum-doublet chemotherapy in SCLC (E1508) [<xref rid="B6" ref-type="bibr">6</xref>]; or figitumumab to chemotherapy and targeted therapies in NSCLC [<xref rid="B7" ref-type="bibr">7</xref>] also failed to provide a significant clinical benefit.</p><p>Although it is tempting to speculate that the incorporation of a predictive biomarker could have produced a different outcome in our study, the repeated failure of various IGF-1R inhibitors is difficult to ignore or to attribute to lack of reliable predictive biomarkers for patient selection. Thus, in our view, linsitinib showed no activity against relapsed SCLC and further development of this agent is not justified.</p></sec><sec id="s3"><title>Trial Information</title><p><def-list><def-item><term>Disease</term><def><p>Lung cancer &#x02013; SCLC</p></def></def-item><def-item><term>Stage of disease / treatment</term><def><p>Metastatic / Advanced</p></def></def-item><def-item><term>Prior Therapy</term><def><p>1 prior regimen</p></def></def-item><def-item><term>Type of study - 1</term><def><p>Phase II</p></def></def-item><def-item><term>Type of study - 2</term><def><p>Randomized</p></def></def-item><def-item><term>Progression-Free Survival</term><def><p>P: 0.1, hazard ratio (HR): 0.6</p></def></def-item><def-item><term>Primary Endpoint</term><def><p>PFS</p></def></def-item><def-item><term>Secondary Endpoint</term><def><p>Overall Survival</p></def></def-item><def-item><term>Additional Details of Endpoints or Study Design</term></def-item><def-item><term>Study Design and Treatment</term><def><p>This Cancer Therapy Evaluation Program (CTEP) multi-institution, randomized phase II clinical trial (ClinicalTrials.gov: NCT01533181) was conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines, the Declaration of Helsinki, and applicable regulatory requirements. Approval from the institutional review board of each participating center was required, and patients provided written informed consent. Patients were randomly assigned to receive either linsitinib (150 mg orally, twice daily, every day until disease progression) or topotecan (1.5 mg/m<sup>2</sup> intravenously or 2.3 mg/m<sup>2</sup> orally, once daily on days 1&#x02013;5 for 4 cycles). The treatment cycle was 21 days (<xref ref-type="fig" rid="F1">Fig. 1</xref>). Linsitinib was provided by CTEP.</p><p>Safety evaluations for treatment-emergent adverse events (AEs) were performed using scheduled hematology, blood chemistry, urinalysis, vital signs, and physical examination assessments. AEs were graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Two dose reductions were permitted per patient for grade 3 or 4 toxicities, with treatment resumed after AE resolution to grade 2 or below, and dose delays of up to 4 weeks were permitted to allow recovery from AEs.</p><p>Primary and/or secondary prophylactic growth factor support was allowed.</p><p>Tumor assessments were performed at screening and after every two cycles, using cross-sectional computed tomography and/or magnetic resonance imaging. Tumor response was evaluated by local investigator assessment and categorized according to RECIST version 1.1.</p></def></def-item><def-item><term>Statistical Analysis</term><def><p>Our primary endpoint was PFS. Secondary endpoints included overall response rate, overall survival, and safety. Patients were randomly assigned 2:1 in favor of linsitinib and stratified on the basis of sensitivity to first-line treatment (sensitive vs. refractory) and performance status (0/1 vs. 2) (<xref ref-type="fig" rid="F2">Fig. 2</xref>).</p><p>An increase in median PFS from 10 weeks (2.5 months) in the topotecan arm (control) to 16.7 weeks (4.2 months) in the linsitinib arm (experimental) was hypothesized. Using a one-sided log-rank test, an overall sample size of 95 patients (31 in the topotecan arm and 64 in the linsitinib arm) would achieve 81.6% power at an &#x003b1; level of 0.1 to detect a hazard ratio (HR) of 0.60 (calculation performed using PASS; NCSS Statistical Software, Kaysville, UT, <ext-link ext-link-type="uri" xlink:href="http://www.ncss.com">http://www.ncss.com</ext-link>).</p><p>Descriptive statistics were used to summarize patient characteristics and treatment administration, tumor response, and safety parameters. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method; between-treatment comparisons for OS and PFS were conducted using the log-rank test.</p></def></def-item><def-item><term>Investigator's Analysis</term><def><p>Inactive because results did not meet primary endpoint.</p></def></def-item></def-list></p></sec><sec id="s5"><title>Drug Information Arm A topotecan</title><p><def-list><def-item><term>Drug 1</term></def-item><def-item><term>Generic/Working name</term><def><p>Topotecan</p></def></def-item><def-item><term>Trade name</term><def><p>Hycamtin</p></def></def-item><def-item><term>Company name</term><def><p>Novartis Pharmaceuticals</p></def></def-item><def-item><term>Drug type</term><def><p>Chemotherapy</p></def></def-item><def-item><term>Drug class</term><def><p>Topoisomerase I</p></def></def-item><def-item><term>Dose</term><def><p>1.5 mg/m<sup>2</sup></p></def></def-item><def-item><term>Route</term><def><p>IV</p></def></def-item><def-item><term>Schedule of Administration</term><def><p>Days 1&#x02013;5</p></def></def-item></def-list></p></sec><sec id="s6"><title>Drug Information Arm B linsitinib</title><p><def-list><def-item><term>Drug 1</term></def-item><def-item><term>Generic/Working name</term><def><p>Linsitinib</p></def></def-item><def-item><term>Trade name</term></def-item><def-item><term>Company name</term><def><p>Astellas Pharmaceuticals</p></def></def-item><def-item><term>Drug type</term><def><p>Small molecule</p></def></def-item><def-item><term>Drug class</term><def><p>Insulin-like growth factors IGF-1R and IGF-2</p></def></def-item><def-item><term>Dose</term><def><p>150 mg per flat dose</p></def></def-item><def-item><term>Route</term><def><p>Oral</p></def></def-item><def-item><term>Schedule of Administration</term><def><p>b.i.d.</p></def></def-item></def-list></p></sec><sec id="s7"><title>Patient Characteristics</title><p><def-list><def-item><term>Number of patients, male</term><def><p>19</p></def></def-item><def-item><term>Number of patients, female</term><def><p>25</p></def></def-item><def-item><term>Stage</term><def><p>Extensive stage</p></def></def-item><def-item><term>Age</term><def><p>Median (range): 64 (34&#x02013;86)</p></def></def-item><def-item><term>Number of prior systemic therapies</term><def><p>Median (range): 1</p></def></def-item><def-item><term>Performance Status: ECOG</term><def><p>0 &#x02014; 36 (0&#x02013;1)</p></def><def><p>1 &#x02014;</p></def><def><p>2 &#x02014; 8</p></def><def><p>3 &#x02014;</p></def><def><p>Unknown &#x02014;</p></def></def-item><def-item><term>Cancer Types or Histologic Subtypes</term><def><p>Small cell 44</p></def></def-item></def-list></p></sec><sec id="s8"><title>Primary Assessment Method</title><p><def-list><term-head><bold>Arm A topotecan: Small Cell</bold></term-head><def-item><term>Number of patients enrolled</term><def><p>15</p></def></def-item><def-item><term>Number of patients evaluable for toxicity</term><def><p>14</p></def></def-item><def-item><term>Number of patients evaluated for efficacy</term><def><p>15</p></def></def-item><def-item><term>Response assessment CR</term><def><p><italic>n</italic> = 0</p></def></def-item><def-item><term>Response assessment PR</term><def><p><italic>n</italic> = 2</p></def></def-item><def-item><term>Response assessment SD</term><def><p><italic>n</italic> = 4</p></def></def-item><def-item><term>Response assessment PD</term><def><p><italic>n</italic> = 9</p></def></def-item><def-item><term>Response assessment OTHER</term><def><p><italic>n</italic> = 0</p></def></def-item><def-item><term>(Median) duration assessments PFS</term><def><p>3 months, CI: 1.5&#x02013;3.6</p></def></def-item><def-item><term>(Median) duration assessments OS</term><def><p>5.3 months, CI: 2.2&#x02013;7.6</p></def></def-item></def-list></p><p><def-list><term-head><bold>Arm B linsitinib: Small Cell</bold></term-head><def-item><term>Number of patients enrolled</term><def><p>29</p></def></def-item><def-item><term>Number of patients evaluable for toxicity</term><def><p>28</p></def></def-item><def-item><term>Number of patients evaluated for efficacy</term><def><p>29</p></def></def-item><def-item><term>Response assessment CR</term><def><p><italic>n</italic> = 0</p></def></def-item><def-item><term>Response assessment PR</term><def><p><italic>n</italic> = 0</p></def></def-item><def-item><term>Response assessment SD</term><def><p><italic>n</italic> = 1</p></def></def-item><def-item><term>Response assessment PD</term><def><p><italic>n</italic> = 28</p></def></def-item><def-item><term>(Median) duration assessments PFS</term><def><p>1.2 months, CI: 1.1&#x02013;1.4</p></def></def-item><def-item><term>(Median) duration assessments OS</term><def><p>3.4 months, CI: 1.8&#x02013;5.6</p></def></def-item></def-list></p></sec><sec id="s9"><title>Assessment, Analysis, and Discussion</title><p><def-list><def-item><term>Completion</term><def><p>Study terminated before completion</p></def></def-item><def-item><term>Pharmacokinetics / Pharmacodynamics</term><def><p>Not collected</p></def></def-item><def-item><term>Investigator's Assessment</term><def><p>Inactive because results did not meet primary endpoint</p></def></def-item></def-list></p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Data Set</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_21_10_1163__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf"
xlink:href="supp_the2016-0220_Chiappori-16-220.pdf"/>
</supplementary-material>
</sec>
</body><back><fn-group><fn fn-type="other"><p><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov"><bold>ClinicalTrials.gov</bold></ext-link>
<bold>Identifier:</bold>
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=NCT01533181">NCT01533181</ext-link></p><p><bold>Sponsor:</bold> CTEP</p><p><bold>Principal Investigator:</bold> Alberto A. Chiappori</p><p><bold>IRB Approved</bold>: Yes</p></fn><fn><p><ext-link ext-link-type="uri" xlink:href="http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results">Click here</ext-link> to access other published clinical trials.</p></fn></fn-group><sec><title>Disclosures</title><p><bold>Alberto A. Chiappori:</bold> Pfizer, Genentech, Boehringer Ingelheim, Merck (C/A); <bold>Gregory A. Otterson:</bold> Genentech, Boehringer (C/A), Bristol-Myers Squibb, Genentech, Boehringer, Xcovery, Pfizer, GlaxoSmithKline/Novartis, NewLink Genetics, Clovis (RF); <bold>Leora Horn:</bold> Bristol-Myers Squibb, Boehringer Ingelheim, Xcovery, Abbvie, Merck, Genentech (C/A), Merck, Genentech, Xcovery, Boehringer Ingelheim, Bristol-Myers Squibb, Astellas, Clovis (RF); <bold>Taofeek K. Owonikoko:</bold> Medivation (C/A); <bold>Jorge Nieva:</bold> Genentech (C/A), Merck (RF), Epic Sciences (OI).</p><p>(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>M</given-names></name><name><surname>Ayoola</surname><given-names>A</given-names></name><name><surname>Belani</surname><given-names>CP</given-names></name></person-group><article-title>Small-cell lung cancer: An update on targeted therapies</article-title><source>Adv Exp Med Biol</source><year>2013</year><volume>779</volume><fpage>385</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">23288650</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zinn</surname><given-names>RL</given-names></name><name><surname>Gardner</surname><given-names>EE</given-names></name><name><surname>Marchionni</surname><given-names>L</given-names></name><etal/></person-group><article-title>ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer</article-title><source>Mol Cancer Ther</source><year>2013</year><volume>12</volume><fpage>1131</fpage><lpage>1139</lpage><pub-id pub-id-type="pmid">23515613</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naito</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>F</given-names></name><name><surname>Ono</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prognostic impact of circulating tumor cells in patients with small cell lung cancer</article-title><source>J Thorac Oncol</source><year>2012</year><volume>7</volume><fpage>512</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">22258473</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKinley</surname><given-names>ET</given-names></name><name><surname>Bugaj</surname><given-names>JE</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name><etal/></person-group><article-title>18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><fpage>3332</fpage><lpage>3340</lpage><pub-id pub-id-type="pmid">21257723</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MH</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Mok</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Metabolic burden measured by (18)f-fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in patients with small cell lung cancer</article-title><source>Cancer Res Treat</source><year>2014</year><volume>46</volume><fpage>165</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">24851108</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belani</surname><given-names>CP</given-names></name><name><surname>Dahlberg</surname><given-names>SE</given-names></name><name><surname>Rudin</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Three-arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either vismodegib (V) or cixutumumab (Cx) for patients with extensive stage-small cell lung cancer (ES-SCLC) (ECOG 1508)</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><issue>suppl</issue><fpage>7508a</fpage></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scagliotti</surname><given-names>GV</given-names></name><name><surname>Bondarenko</surname><given-names>I</given-names></name><name><surname>Blackhall</surname><given-names>F</given-names></name><etal/></person-group><article-title>Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer</article-title><source>Ann Oncol</source><year>2015</year><volume>26</volume><fpage>497</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">25395283</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" fig-type="figure" position="float"><caption><p>Kaplan-Meier curves for survival from the time of randomization by treatment arm. <bold>(A)</bold>: Progression-free survival. <bold>(B)</bold>: Overall survival.</p></caption><graphic xlink:href="theoncologist_16220CTR_f1"/></fig><fig id="F2" fig-type="figure" position="float"><label>Figure 1.</label><caption><p>Trial design.</p><p>Abbreviations: ECOG, Eastern Cooperative Oncology Group; PD, progressive disease; Plat., platinum; PO, by mouth; PS, performance status.</p></caption><graphic xlink:href="theoncologist_16220CTR_f2"/></fig><fig id="F3" fig-type="figure" position="float"><label>Figure 2.</label><caption><p>Kaplan-Meier curves for survival from the time of randomization by treatment arm. <bold>(A)</bold>: Progression-free survival. <bold>(B)</bold>: Overall survival.</p></caption><graphic xlink:href="theoncologist_16220CTR_f3"/></fig><table-wrap id="T1" position="float"><label>Table 1.</label><caption><p>Patient characteristics</p></caption><graphic xlink:href="theoncologist_T16220CTRt1"/></table-wrap><table-wrap id="T2" position="float"><label>Table 2.</label><caption><p>Adverse events occurring in &#x02265;2% of patients treated with linsitinib and topotecan</p></caption><graphic xlink:href="theoncologist_T16220CTRt2"/></table-wrap></floats-group></article>